Skip to main content

APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROSI Genomic Alterations

NCT03213652

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROSI Genomic Alterations

Associated Conditions

Multiple Tumor Types

Principal Investigator

Sponsor

Children's Oncology Group

You are being asked to participate in this study because you have a relapsed or refractory tumor without a proven treatment strategy for cure. The main goal of this study is to test any good and bad effects of the ensartinib on your tumor. A second goal of the study is to evaluate side effects that might be caused by ensartinib and to learn more about the pharmacology (how your body handles the drug) of ensartinib.

This study is currently enrolling.